 |
인쇄하기
취소
|
Sebivo fails to get health insurance
Sebivo (telbivudine), a new antiviral drug used in the treatment of hepatitis infection, failed to receive health insurance benefit, according to Novartis Korea.
The Health Insurance Review and Assessment Service said on March 19 that Sevivo lacks the rationale for economic effectiveness over other competitive medicines, such as Zeffix or Hepsera.
Telbivudine is indicated for the treatmen...
The Health Insurance Review and Assessment Service said on March 19 that Sevivo lacks the rationale for economic effectiveness over other competitive medicines, such as Zeffix or Hepsera.
Telbivudine is indicated for the treatmen...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.